Mushroom Supplement Regulation
1997
In April 2025, UV-treated Vitamin D2 mushroom powder became the most recently authorized mushroom novel food in the EU, completing a multi-year EFSA safety assessment under Commission Implementing Regulation 2025/691.
EU Commission Implementing Regulation 2025/691, April 2025
3–5 years
typical timeline for EFSA novel food authorization
May 15, 1997
foods consumed before this date are not classified as novel
Regulation 2015/2283
the EU law currently governing novel food authorization
EU Commission Implementing Regulation 2025/691, April 2025
View as image ↗The EU Novel Food Regulation asks a single question about every mushroom supplement ingredient sold in Europe: was this specific ingredient, in this specific form, consumed in the EU in significant quantities before May 15, 1997? If the answer is yes, it is a traditional food and can be sold without special authorization. If the answer is no, it is a "novel food" under EU law, and it cannot be sold until the European Commission authorizes it following a safety review by the European Food Safety Authority.
This framework creates a fundamentally different market entry environment than what mushroom supplement manufacturers face in the US. Under the FDA's DSHEA framework, no pre-market approval is required for dietary supplements; manufacturers are responsible for safety but do not submit evidence to regulators before selling. In the EU, the authorization must come first.
The practical result is a two-tier supplement market. Common culinary mushrooms in familiar forms move freely across EU member states. Unusual species, mycelium-based powders from otherwise traditional species, and novel extraction methods can all fall into "novel food" territory, requiring years of regulatory process before they can legally reach European consumers.
Key Takeaways
- EU Novel Food Regulation 2015/2283 requires pre-market authorization for any food ingredient not consumed in the EU in significant quantities before May 15, 1997
- Common culinary mushrooms (Button, Shiitake, Oyster, Portobello) sold as whole or dried fruiting bodies are generally not novel foods and do not require authorization
- Mycelium powders and concentrated extracts of unusual species frequently ARE classified as novel foods, even when the same species' fruiting body is traditional
- Getting a novel food authorized through EFSA typically involves a 3–5 year process of safety assessment, scientific review, and Commission rulemaking
- In April 2025, UV-treated Vitamin D2 mushroom powder became the most recently authorized mushroom novel food in the EU under Commission Implementing Regulation 2025/691
- A mushroom supplement that legally sells across the EU has passed pre-market scrutiny that no US-only product faces, making EU compliance a meaningful quality signal for buyers
The May 15, 1997 Threshold: Why a Single Date Governs Everything
EU Novel Food Regulation 2015/2283 requires pre-market authorization for any food ingredient not consumed in the EU in significant quantities before May 15, 1997. Traditional culinary mushrooms are generally not novel. Mycelium powders of unusual species and concentrated extracts of even common species frequently are.
The novel food system was created because the European food supply changed rapidly in the late 1990s and 2000s. New processing technologies, global ingredient sourcing, and the rise of dietary supplements brought dozens of ingredients to European markets that had no established history there. Regulators needed a principled way to distinguish genuinely new additions to the food supply from traditional foods with long safety records. The May 15, 1997 date, when the original Novel Food Regulation entered into force, became that dividing line.
EU Regulation 2015/2283 updated and strengthened the framework that the original 1997 regulation had established. The definition of "novel food" covers any food that was not used for human consumption to a significant degree within the EU before that date. "Significant degree" does not appear with a precise numerical definition in the regulation text, but EFSA guidance and case decisions have established that widespread commercial consumption across multiple member states, documented through import data, sales records, or formal consumption surveys, is the standard.
Two implications follow from this definition that shape how the regulation works in practice.
Novel food status is determined ingredient by ingredient and form by form, not species by species. A single mushroom species can have some forms classified as traditional and other forms classified as novel, simultaneously. The fruiting body of a species consumed in European kitchens for decades may not be a novel food. A concentrated mycelium powder of the same species, produced through submerged fermentation that did not exist in 1997, may be.
Traditional use in countries outside the EU does not automatically exempt an ingredient. A species with deep roots in Chinese or Japanese traditional medicine still needs to demonstrate significant EU consumption history, not just global use. Consumption within European immigrant communities carries some weight in novel food evaluations, but it is generally not sufficient on its own to establish the pre-1997 EU consumption history the regulation requires.
Which Mushroom Forms Are Not Novel Foods (And Can Sell Without Authorization)
The mushrooms most familiar to European consumers are not the problem. Button mushrooms (Agaricus bisporus), Shiitake (Lentinula edodes), Oyster mushrooms (Pleurotus ostreatus), and Portobello (a mature variety of Agaricus bisporus) were part of ordinary European food culture long before 1997. Their fruiting bodies, whether fresh, dried, or powdered in their natural form, carry well-established consumption histories and are not classified as novel foods. They can be sold freely throughout the EU without authorization.
For species with more complex histories, the relevant question is always form-specific. Reishi (Ganoderma lucidum) has a history of traditional use in East Asian medicine reaching back centuries, but European consumption before 1997 was limited to specialist health food stores rather than mainstream cuisine. Whether a given Reishi preparation triggers the novel food definition depends on how it was processed and what pre-1997 consumption data exists to support a traditional-use claim. Cordyceps (Cordyceps sinensis) sits in a similar position.
The EU Novel Food Catalogue, maintained by the European Commission, is the authoritative reference for current status determinations by ingredient and form. It is a searchable database, updated as new decisions are made, and it is the first place brands and buyers should check for any specific ingredient. For a full species-by-species breakdown of current novel food status, including a reference table, see EU Novel Food Regulations and Mushroom Supplements: What's Approved and What Isn't.
The "Significant Quantities" Standard in Practice
Regulators look for documentation that establishes commercial-scale consumption history: import and trade data, inclusion in published recipes and cookbooks, consumer survey evidence, historical sales records, or documentation in national food composition databases. Traditional use in a specific EU region may qualify, but it needs to be documented formally, not just asserted.
For common culinary species, this history is uncontested and does not require active demonstration. For specialty supplement ingredients that entered European markets primarily in the 2000s through health food channels, establishing pre-1997 significant EU consumption is often simply impossible. The consumption did not happen at scale, and no record exists to cite. Those ingredients fall into the novel food category by default.
The Complication: When the Same Mushroom Becomes Novel in a Different Form
This is the element of EU novel food regulation that catches most supplement manufacturers off guard, and that almost no editorial coverage addresses clearly.
A mushroom species that is traditionally consumed as a whole or dried fruiting body may not retain that traditional-use status when it is:
Processed into a mycelium powder through liquid fermentation rather than fruiting body harvest. The cultivation method, substrate, and resulting compound profile differ substantially from the fruiting body. EFSA treats these as potentially distinct ingredients, not as the same food in a different container.
Extracted using solvents to isolate and concentrate specific bioactive compounds. A hot-water extract of Shiitake has a different composition than whole dried Shiitake. A high-purity polysaccharide fraction isolated through multiple extraction steps looks, chemically, quite different from the raw ingredient with the consumption history.
Subjected to UV radiation to produce elevated Vitamin D2 concentrations. This process produces measurably different bioactive levels than ordinary mushroom powder, which is precisely why UV-treated Vitamin D2 mushroom powder required novel food authorization before April 2025.
Antrodia camphorata is the clearest example of a species with no traditional EU consumption history in any form. Native to Taiwan, Antrodia entered European supplement markets in the 2010s. Its mycelia powder is classified as a novel food requiring full authorization. No traditional-use exemption applies because no pre-1997 EU consumption exists to claim. Antrodia cannot legally be sold as a food ingredient in the EU without completing the full authorization process.
The broader principle: supplement brands cannot assume that because a fruiting body preparation is traditional, a mycelium extraction or novel isolate of the same species is also covered. Each distinct form may require its own novel food evaluation. The EU Novel Food Catalogue reflects this distinction in its status entries.
The April 2025 Case Study: How Vitamin D2 Mushroom Powder Got Authorized
In April 2025, the European Commission published Commission Implementing Regulation 2025/691, authorizing UV-treated Vitamin D2 mushroom powder as a novel food for use across the EU. This is the most recently completed mushroom novel food authorization, and it shows what the process looks like from application to approval.
Vitamin D2 mushroom powder is produced by exposing mushrooms to ultraviolet light, which converts ergosterol (a compound naturally present in fungal cell walls) into ergocalciferol, a form of Vitamin D2. The resulting powder is standardized to specific Vitamin D2 concentrations substantially higher than what ordinary dried mushroom powder contains. That combination of deliberate UV processing and elevated bioactive concentration placed it squarely in novel food territory. Even though the base ingredient (mushroom) is traditional, the specific form produced by this UV treatment, at the concentrations achieved, was not part of the EU food supply before 1997.
The authorization specifies exact permitted conditions of use. It lists which food categories can contain the ingredient, the maximum permitted concentration in each category, and required labeling information. Novel food authorizations are not blanket permissions. They are bounded approvals tied to the specific form, use levels, and applications that the applicant's safety data covered. A manufacturer cannot take the Vitamin D2 mushroom powder authorization and apply it to a different mushroom extract, even from the same species.
The EFSA scientific opinion preceding the Commission's action assessed the safety of the ingredient at the proposed use levels, examining bioavailability, potential adverse effects, and dietary exposure across different population groups, including children and pregnant women. That opinion was published and publicly available before the Commission moved to issue a regulation.
This authorization matters beyond the specific ingredient. It demonstrates that the EU novel food process is genuinely available for mushroom ingredients, but it requires a complete dossier, EFSA scientific review, and Commission rulemaking. No ingredient bypasses this sequence.
What the EFSA Authorization Process Actually Requires
The European Food Safety Authority conducts the scientific review for all novel food applications. The applicant submits a complete dossier and EFSA evaluates it before providing a scientific opinion to the Commission.
A full novel food dossier covers: the precise identity and characterization of the ingredient, including production method, specification, and compositional analysis; the production process in detail; proposed conditions of use and the food categories where the ingredient would appear; any existing history of use in countries outside the EU; proposed labeling; and comprehensive safety data.
The safety data requirements are the most demanding part. EFSA expects toxicological studies demonstrating that the ingredient does not cause harm at intended exposure levels, absorption and metabolism data showing how the body processes it, nutritional assessment, allergenicity evaluation, and human dietary exposure estimates across different population groups. For ingredients with limited prior safety history, generating this data means commissioning original research, not assembling existing literature.
The timeline reflects the complexity of the review. EFSA's formal target for issuing a scientific opinion is nine months from receiving a valid application, but pre-screening, completeness review of the application, and the subsequent Commission rulemaking step add substantially to real-world timelines. Applications submitted in 2020 have, in many cases, not yet reached final Commission authorization by 2025. A realistic planning horizon for a first-time novel food application is 3–5 years from initial submission to authorized sale.
The financial cost is significant. Assembling a complete EFSA dossier, particularly one that requires generating original safety data, is not a small undertaking. Industry estimates for novel food applications typically range from several hundred thousand euros to over one million euros, depending on the ingredient and the gaps in existing safety evidence. This scale of investment selects for large companies or well-funded applicants with a clear, long-horizon commercial case for EU market access. For brands navigating multi-jurisdiction launches, these requirements are covered in depth in Selling Mushroom Supplements Globally: Regulatory Challenges.
What This Means If You're Buying Mushroom Supplements in Europe
The EU Novel Food framework creates a meaningful quality signal for consumers, though it works indirectly rather than as a direct endorsement of any product's effectiveness.
A mushroom supplement that legally sells across EU member states has satisfied one of two conditions: either the manufacturer has documented that the ingredient was consumed in the EU in significant quantities before May 1997, or the ingredient has completed EFSA's safety assessment and received Commission authorization. Neither condition is trivially satisfied.
This is structurally different from what the US market requires. Under DSHEA, a US-only mushroom supplement manufacturer is responsible for ensuring safety, but no pre-market evidence review by regulators occurs before the product reaches consumers. EU compliance means an external institutional check happened before the product reached the shelf. The check was on ingredient safety, not product efficacy, and it was conducted by a regulatory body rather than the manufacturer's own quality assurance team.
For buyers purchasing supplements online or navigating cross-border shipping, this distinction is worth understanding. A product sold by an EU-registered company to EU consumers, carrying EU novel food compliance for its ingredients, has been through a regulatory gate that no US-only product was required to pass. How much weight that carries depends on the specific ingredient and what the authorization covered, but the gate exists and it has real requirements.
Buyers who want to go further in verifying product quality can look at complementary signals. Whether a product has Canadian Natural Product Number (NPN) certification, Australian TGA listing, or third-party quality testing adds additional verification layers. DNA testing for mushroom supplement species identity is one method manufacturers use to confirm that a product contains what the label claims — something EU novel food authorization does not directly address.
The adulteration and quality-gap problem in the mushroom supplement market is explored in Mushroom Supplement Adulteration: How Widespread Is the Problem?, which covers how regulatory gaps in less stringent markets contribute to quality inconsistencies.
The EU Novel Food Catalogue is publicly available through the European Commission's website and is searchable by ingredient. Buyers or brands who want to verify the current status of a specific mushroom ingredient or form can check it directly. Regulatory status changes as new applications are decided and new authorizations issued, so current status requires checking the official source rather than relying on secondary accounts.
How EU Novel Food Rules Differ From US Regulation
The structural difference between the EU and US approaches is pre-market versus post-market oversight.
The EU requires a safety case to be reviewed and approved before a novel ingredient can be sold. The US requires the manufacturer to establish safety before bringing a product to market, but that determination is internal and not submitted to regulators before selling. FDA can act against products after they are on the market when safety concerns emerge, but no pre-market review is required for supplements under DSHEA.
GRAS status for mushroom ingredients provides one pathway in the US for establishing that a food-use ingredient is generally recognized as safe, but the self-affirmation route does not involve pre-market regulatory review. The EU has no equivalent self-affirmation pathway for novel foods; every novel ingredient goes through EFSA.
The result is that EU market entry for novel mushroom ingredients is slower and more expensive than US market entry, but it produces a formal, documented regulatory record of the safety evaluation. A brand that has completed EU novel food authorization has an institutional record of what data was assessed and what uses were approved.
For a full comparison of how the US, EU, Canada, and Australia regulate mushroom supplements differently, including a jurisdiction comparison table, see How International Mushroom Regulations Differ from US Rules.
The Bottom Line
EU Novel Food Regulation 2015/2283 creates a pre-market authorization requirement for mushroom ingredients not consumed in the EU in significant quantities before May 15, 1997. Traditional culinary mushrooms in standard forms are generally exempt, but mycelium powders, concentrated extracts, and unusual species frequently require full EFSA safety assessment and Commission authorization before they can be legally sold in Europe. The process typically spans 3–5 years, and a product that has completed it carries a level of pre-market regulatory scrutiny that no US-only supplement product is required to meet.